GlassScriptPhysician profile
Jonathan W Tronolone
NPI 1376626432
$1,114.80
in general payments reported to CMS, 2019-2025
12 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $27.67 · 2021: $85.03 · 2022: $220 · 2023: $40.44 · 2024: $48.42 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $431.49 | 2019-2022 | |
| Imperative Care, INC | $149.95 | 2024-2025 | Symphony Catheter, Prodigy Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Shockwave Medical, INC | $102.91 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $83.29 | 2021-2025 | |
| Bard Peripheral Vascular, INC. | $44.09 | 2022-2023 | Venclose Maven Catheter |
| Boston Scientific Corporation | $43.97 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor |
| Astellas Pharma US INC | $43.16 | 2021 | |
| Amgen INC. | $29.91 | 2019 | |
| W. L. Gore & Associates, INC. | $29.76 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Janssen Pharmaceuticals, INC | $16.19 | 2019 | |
| Vifor Pharma, INC. | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tronolone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.